Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

Core Viewpoint - Ascendis Pharma A/S has announced a share repurchase program and net settlement of restricted stock units (RSUs) to preserve approximately 200,000 American Depositary Shares (ADSs) held as treasury shares, with a total expected use of approximately $25 million in the first quarter of 2025 [1][3]. Share Repurchase Program - The Board of Directors has authorized the repurchase of up to$18.25 million of the Company's ADSs, which represent ordinary shares of Ascendis Pharma A/S [2][4]. - The repurchases will be executed in compliance with U.S. securities regulations and may include various methods such as open market purchases and block trades [4]. - The timing and amount of repurchases will depend on market conditions and other factors, and the program can be modified or terminated at any time without notice [4]. Net Settlement of RSUs - The Company plans to apply net settlement for tax-withholding obligations related to the vesting of approximately 450,000 RSUs, amounting to about $9 million, which will preserve approximately 75,000 ADSs as treasury shares [3]. - Together with the share repurchase program, this initiative aims to maintain a total of approximately 200,000 ADSs held as treasury shares [3]. Company Overview - Ascendis Pharma is focused on developing innovative therapies using its TransCon technology platform, aiming to make a significant impact on patients' lives [5]. - The company is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States [5].